On Friday, Shares of Novavax, Inc. (NASDAQ:NVAX), added 0.97% and closed at $2.08 in the last trading session. The last trading range of the stock ranges between $1.98 and $2.09. Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, in addition to pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, in addition to combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, counting the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants.
Yamana Gold Inc. (USA) (NYSE:AUY), DROPPED -2.71% and closed at $4.31 in the last trading session. The last trading range of the stock ranges between $4.31 and $4.57. The company’s Market capitalization is $3.97 Billion with the total Outstanding Shares of 947.60 Million. YAMANA GOLD INC. (YRI.TO)(AUY) (“Yamana” or “the Company”) will release its third quarter 2016 results after market close on October 27, 2016 followed by a conference call and webcast on October 28, 2016 at 9:00 a.m. ET.